bluebird bio Inc. (BLUE)

102.15
0.08 0.08
NASDAQ : Health Technology
Prev Close 102.23
Open 102.23
Day Low/High 99.15 / 104.90
52 Wk Low/High 100.99 / 236.17
Volume 638.41K
Avg Volume 761.60K
Exchange NASDAQ
Shares Outstanding 54.69M
Market Cap 5.95B
EPS -7.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Bluebird Bio Presents New Data For LentiGlobin Gene Therapy In Transfusion Dependent β-Thalassemia At 60th Annual Meeting Of The American Society Of Hematology

Bluebird Bio Presents New Data For LentiGlobin Gene Therapy In Transfusion Dependent β-Thalassemia At 60th Annual Meeting Of The American Society Of Hematology

bluebird bio, Inc. (Nasdaq: BLUE) announced new data from the Phase 3 Northstar-2 (HGB-207) and Northstar-3 (HGB-212) clinical studies of its investigational LentiGlobin ™ gene therapy in the treatment of patients with transfusion-dependent β-thalassemia...

Bluebird Bio And Celgene Corporation Present Initial Data From Ongoing Phase 1 Clinical Study Of Next-Generation Anti-BCMA CAR T Cell Therapy Bb21217 In Patients With Relapsed/Refractory Multiple Myeloma At ASH Annual Meeting

Bluebird Bio And Celgene Corporation Present Initial Data From Ongoing Phase 1 Clinical Study Of Next-Generation Anti-BCMA CAR T Cell Therapy Bb21217 In Patients With Relapsed/Refractory Multiple Myeloma At ASH Annual Meeting

bluebird bio, Inc. (Nasdaq:BLUE) and Celgene Corporation (NASDAQ:CELG) announced initial data from the ongoing Phase 1 clinical study of bb21217 (CRB-402), an investigational next-generation anti-BCMA CAR T cell therapy being studied in patients with...

Bluebird Bio Presents Updated Data From Clinical Studies Of LentiGlobin Gene Therapy In Transfusion-Dependent β-Thalassemia And Sickle Cell Disease At 60th Annual Meeting Of The American Society Of Hematology

Bluebird Bio Presents Updated Data From Clinical Studies Of LentiGlobin Gene Therapy In Transfusion-Dependent β-Thalassemia And Sickle Cell Disease At 60th Annual Meeting Of The American Society Of Hematology

bluebird bio, Inc. (Nasdaq: BLUE) announced new long-term data from the completed Phase 1/2 Northstar (HGB-204) study of investigational LentiGlobin ™ gene therapy in patients with transfusion-dependent β-thalassemia (TDT) and from the ongoing Phase 1/2...

Bluebird Bio To Host Live Webcast Of Investor And Analyst Event At The 60th Annual Meeting Of The American Society Of Hematology

Bluebird Bio To Host Live Webcast Of Investor And Analyst Event At The 60th Annual Meeting Of The American Society Of Hematology

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast of an investor and analyst event being held on Monday, December 3, 2018, during the 60 th Annual Meeting of the American Society of Hematology (ASH).

Bluebird Bio To Present At The Evercore ISI HealthCONx Conference

Bluebird Bio To Present At The Evercore ISI HealthCONx Conference

bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the Evercore ISI HealthCONx Conference, Wednesday, November 28, at 4:15 p.

Bluebird Bio Reports Third Quarter 2018 Financial Results And Highlights Operational Progress

Bluebird Bio Reports Third Quarter 2018 Financial Results And Highlights Operational Progress

bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the third quarter ended September 30, 2018.

Bluebird Bio To Present New Data From Early- And Late-Stage Pipeline Of Investigational Gene And Cell Therapies At The American Society Of Hematology Annual Meeting

Bluebird Bio To Present New Data From Early- And Late-Stage Pipeline Of Investigational Gene And Cell Therapies At The American Society Of Hematology Annual Meeting

bluebird bio, Inc. (Nasdaq: BLUE) today announced that new data from its early- and late-stage investigational gene and cell therapy programs will be presented during the 60 th Annual Meeting of the American Society of Hematology (ASH) in San Diego,...

The Bears Have it Backwards: Cramer's 'Mad Money' Recap (Monday 9/24/18)

The Bears Have it Backwards: Cramer's 'Mad Money' Recap (Monday 9/24/18)

Jim Cramer says traders hate hearing about long-term investing because they want instant payoffs.

Bluebird Bio Announces European Medicines Agency's Acceptance Of Marketing Authorization Application For LentiGlobin™ Gene Therapy For The Treatment Of Transfusion-Dependent β-Thalassemia

Bluebird Bio Announces European Medicines Agency's Acceptance Of Marketing Authorization Application For LentiGlobin™ Gene Therapy For The Treatment Of Transfusion-Dependent β-Thalassemia

bluebird bio, Inc. (Nasdaq: BLUE) announced today that the European Medicines Agency (EMA) accepted the company's marketing authorization application (MAA) for its investigational LentiGlobin™ gene therapy for the treatment of adolescents and adults with...

Bluebird Bio To Present At The LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

Bluebird Bio To Present At The LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology, Wednesday, October 3, at 3:30 p.

Bullish Divergences on Bluebird Bio Tell Me This Stock Can Sing

Bullish Divergences on Bluebird Bio Tell Me This Stock Can Sing

Charts are pointing the way to an upside recovery for this stock.

Total SA, Bluebird Bio, U.S. Silica Holdings: 'Mad Money' Lightning Round

Total SA, Bluebird Bio, U.S. Silica Holdings: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Total SA, Bluebird Bio, U.S. Silica Holdings, Nucor, International Paper, Nokia, Alibaba.

Bluebird Bio Presents Updated Data From Phase 2/3 Starbeam Study Of Investigational Lenti-D™ Gene Therapy For CALD And Initial Data From Observational Study ALD-103 Of Allogeneic Hematopoietic Stem Cell Transplant In CALD At 2018 SSIEM

Bluebird Bio Presents Updated Data From Phase 2/3 Starbeam Study Of Investigational Lenti-D™ Gene Therapy For CALD And Initial Data From Observational Study ALD-103 Of Allogeneic Hematopoietic Stem Cell Transplant In CALD At 2018 SSIEM

bluebird bio, Inc. (Nasdaq: BLUE) announced updated results from the Phase 2/3 Starbeam study (ALD-102) of its investigational Lenti-D™ gene therapy in boys 17 years of age and under with cerebral adrenoleukodystrophy (CALD), and initial data from...

Bluebird Bio To Present At Investor Conferences In September

Bluebird Bio To Present At Investor Conferences In September

bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: Citi 13 th Annual Biotech Conference, Wednesday, September 5, 10:30 a.

Bluebird Bio And Gritstone Oncology Announce Strategic Collaboration To Develop Novel Cancer Cell Therapies

Bluebird Bio And Gritstone Oncology Announce Strategic Collaboration To Develop Novel Cancer Cell Therapies

bluebird bio, Inc. (Nasdaq: BLUE) and Gritstone Oncology, Inc.

Bluebird Bio And Regeneron Announce Collaboration To Discover, Develop And Commercialize New Cell Therapies For Cancer

Bluebird Bio And Regeneron Announce Collaboration To Discover, Develop And Commercialize New Cell Therapies For Cancer

bluebird bio, Inc. (NASDAQ: BLUE) and Regeneron Pharmaceuticals, Inc.

Bluebird Bio To Present Updated Data For Lenti-D™ Gene Therapy For Cerebral Adrenoleukodystrophy At SSIEM 2018 Symposium

Bluebird Bio To Present Updated Data For Lenti-D™ Gene Therapy For Cerebral Adrenoleukodystrophy At SSIEM 2018 Symposium

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from its clinical development program for its investigational Lenti-D™ gene therapy in pediatric patients with cerebral adrenoleukodystrophy (CALD) will be presented at the Society for the Study of...

Bluebird Bio To Present At The 2018 Wedbush PacGrow Healthcare Conference

Bluebird Bio To Present At The 2018 Wedbush PacGrow Healthcare Conference

bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the 2018 Wedbush PacGrow Healthcare Conference, Tuesday, August 14, at 8:35 a.

Bluebird Bio Reports Second Quarter 2018 Financial Results And Highlights Operational Progress

Bluebird Bio Reports Second Quarter 2018 Financial Results And Highlights Operational Progress

bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the second quarter ended June 30, 2018.

Bluebird Bio Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Bluebird Bio Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

bluebird bio, Inc. (Nasdaq: BLUE) today announced the closing of its previously announced underwritten public offering of 3,892,308 shares of its common stock, including 507,692 shares of common stock sold pursuant to the underwriters' full exercise of...

Bluebird Bio's LentiGlobin™ Gene Therapy Granted Accelerated Assessment By European Medicines Agency For The Treatment Of Transfusion-Dependent β-Thalassemia

Bluebird Bio's LentiGlobin™ Gene Therapy Granted Accelerated Assessment By European Medicines Agency For The Treatment Of Transfusion-Dependent β-Thalassemia

bluebird bio, Inc. (Nasdaq: BLUE) today announced that its investigational LentiGlobin™ gene therapy for the treatment of adolescent and adult patients with transfusion-dependent β-thalassemia (TDT) and a non-β 0/β 0 genotype, was granted an accelerated...

Trump's Trade War Against U.S. Allies Is a Direct Hit to Key Industries

Trump's Trade War Against U.S. Allies Is a Direct Hit to Key Industries

Diplomacy must precede presidential threats.

Bluebird Bio Announces Pricing Of Public Offering Of Common Stock

Bluebird Bio Announces Pricing Of Public Offering Of Common Stock

bluebird bio, Inc. (Nasdaq: BLUE) today announced the pricing of an underwritten public offering of 3,384,616 shares of its common stock at a public offering price of $162.

Bluebird Bio Announces Proposed Public Offering Of Common Stock

Bluebird Bio Announces Proposed Public Offering Of Common Stock

bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has commenced an underwritten public offering of $400 million of its common stock.

Kraft Heinz, VF Corp, Cimarex Energy: 'Mad Money' Lightning Round

Kraft Heinz, VF Corp, Cimarex Energy: 'Mad Money' Lightning Round

Jim Cramer takes a look at Kraft Heinz, VF Corp, Cimarex Energy, STORE Capital, Wheaton Precious Metals, Bluebird Bio, First Commonwealth Financial Corp.

Industrials in Value Territory: Cramer's 'Mad Money' Recap (Thursday 6/21/18)

Industrials in Value Territory: Cramer's 'Mad Money' Recap (Thursday 6/21/18)

Jim Cramer says many stocks already reflect the worst-case scenarios, and that means he sees a lot of upside potential.

Bluebird Bio Announces New Interim Data From Phase 1 (HGB-206) Study Of LentiGlobin™ Gene Therapy In Patients With Severe Sickle Cell Disease At Annual Congress Of The European Hematology Association

Bluebird Bio Announces New Interim Data From Phase 1 (HGB-206) Study Of LentiGlobin™ Gene Therapy In Patients With Severe Sickle Cell Disease At Annual Congress Of The European Hematology Association

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral...

TheStreet Quant Rating: D+ (Sell)